This is some really good info I need to file quickly.
harry261 to name just one. Even some INO supporters no longer appear? Is this good or bad info?
use of the word "probably" in your post is not included in the vocabulary of facts. It's only found in the short handbook of hopeful speculation.
U.S. shares extended a selloff today, with the Nasdaq Composite Index sliding the most in two months, as Raymond James & Associates said equities are vulnerable to losses and Citigroup Inc. cited investor concerns for a "severe" pullback.
Scott Olson, the Street author, graduated from the University of Massachusetts in 1999 with a bachelors in English prior to moving to California and working with the founders of Trade Ideas at FutureTrade Tech. I heard he shares a cube with AF @ The Street.
was is banned or did they just give up on the concept? what happens to people that were using the service?
5 percent drop on increased sales ... tells me there is some insider news that will eventually be under scrutiny by Congress and others.
can the INO TEAM respond to this adventure like they did earlier to the AF swipe? Some investors might be interested to know what fish they're trying to hook.
why do people post "saving" negative stock information on a public message board? What do they have to gain by doing so? Is it their resurrection? A way to trick investors? Total rubbish is what I say.
Interesting that your post is listed on the YMB as being done by adsmith2036. Funny how info can help clarify some posts.
You hedgies, adjack, are comical always trying to cover your tracks. Hilarious how adsmith2036 quickly replies to jackegan99 1 hour and 31 minutes after my observation the two poster names coincide visually on the YMB. All you hedgies do is pump it up and later bash it down, or vice versa. Funny how info can help clarify posts.
News about Castle Brands Inc., including commentary and archival articles published in The New York Times.
Castle Brands Inc. develops and markets beverage alcohol categories. Its beverage alcohol categories includes rum, whiskey, liqueurs, vodka and tequila. It distributes its products in all 50 states in the United States and the District of Columbia, in thirteen primary international markets, including Ireland, Great Britain, Northern Ireland, Germany, Canada, South Africa, Bulgaria, France, Russia, Finland, Norway, Sweden, China and the Duty Free markets, and in a number of other countries in continental Europe and Latin America. It markets brands, including Gosling's Rum, Gosling's Stormy Ginger Beer, Gosling's Dark ‘n Stormy ready-to-drink cocktail, Jefferson's, Jefferson's Reserve and Jefferson's Presidential Select bourbons, Jefferson's Rye whiskey, Pallini liqueurs, Clontarf Irish whiskey, Knappogue Castle Whiskey, Brady's Irish Cream, Boru vodka, Tierras TM tequila, Celtic Honey liqueur, Castello Mio sambucas, Travis Hasse's Original Pie liqueurs and Gozio amaretto.
I believe COCP already has a partnership with TEVA that was consummated 15SEP11. Maybe the terms will be updated? Under the terms of the initial agreement, Teva will initially invest $7.5 million in CDI (now Cocrystal), and the Company will develop for Teva an antiviral drug targeting the polymerase enzyme of the Hepatitis C virus. Upon completion of the initial development plan, Teva will have the option to make additional investments under certain milestones. Teva will have the right to exclusively license the drug for further development and commercialization, under agreed-upon commercial terms. “We are delighted with this investment from Teva, a leading global company that develops important new medicines bringing value to patients,” said Nobel Laureate Roger Kornberg, Ph.D., Chief Scientist at CDI and member of the Board of Directors of Teva. “Through this agreement, CDI is now ideally placed to accelerate the development of our novel platform, which combines high resolution X-ray crystallography with unique and advanced computational methods. It is our hope we can yield new and better drugs for the treatment and prevention of many viral diseases."
My point exactly, billyteex1, since under the initial partnership Teva has the option to further invest for the development of two additional antiviral or antibacterial drugs that will result in Teva owning approximately 23% of Cocrystal. I'm not sure even sure whether 23% is still valid today given the lawsuit, recent Frost purchases, and other factors that have occurred since 2011. Are you referring to a possible separate partnership in your initial "MSLP" post? I'm sure TEVA is already apprised on the status of preclinical work at Cocrystal. Thanks for clarifying.